VRDN Viridian Therapeutics, Inc.\DE
Pharmaceutical Preparations · Nasdaq · SEC CIK 1590750 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-62.8%
TTM net income YoY-50.2%
TTM EPS YoY—
Revenue 3-yr CAGR323.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,781.4%
Net margin-1,724.1%
FCF margin-1,305.4%
EBITDA margin-1,778.7%
Returns
ROE-83.7%
ROA-56.5%
ROIC (approx.)-97.2%
Asset turnover0.03x
Leverage & solvency
Liabilities / assets43.5%
Debt / equity0.00x
Current ratio14.46x
Interest coverage-19.27x
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-14.0%
Payout ratio—
Capex / revenue7.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $70.85M | $302,000 | $314,000 | $1.77M | $2.96M |
| R&D expense | $338.93M | $238.25M | $159.76M | $100.89M | $56.89M |
| SG&A expense | $95.31M | $61.08M | $95.00M | $35.18M | $25.80M |
| Operating income | -$363.39M | -$299.04M | -$254.45M | -$134.30M | -$79.73M |
| Interest expense | $4.95M | $2.20M | $1.33M | $486,000 | $3,000 |
| Income tax | $0 | — | — | — | — |
| Net income | -$342.60M | -$269.95M | -$237.73M | -$129.87M | -$79.41M |
| EBITDA | -$362.94M | -$298.50M | -$253.93M | -$134.05M | -$79.61M |
| EPS (basic) | — | — | -5.31 | -4.05 | -6.66 |
| EPS (diluted) | — | — | -5.31 | -4.05 | -6.66 |
| Weighted avg. shares (diluted) | — | — | 44.76M | 32.09M | 11.92M |
| Balance sheet | |||||
| Cash & equivalents | $212.38M | $99.59M | $102.83M | $155.58M | $42.30M |
| Short-term investments | $662.27M | $617.99M | $374.54M | $268.97M | $154.67M |
| Receivables | $0 | — | — | — | — |
| Inventory | $0 | — | — | — | — |
| Current assets | $894.23M | $738.46M | $486.48M | $431.17M | $200.16M |
| PP&E, net | $1.23M | $1.24M | $1.67M | $1.33M | $375,000 |
| Intangibles | $0 | — | — | — | — |
| Total assets | $899.42M | $742.40M | $490.42M | $435.09M | $203.71M |
| Current liabilities | $70.70M | $47.87M | $26.64M | $33.35M | $13.64M |
| Short-term debt | — | $0 | $0 | — | — |
| Long-term debt | — | $20.58M | $20.20M | $4.64M | $0 |
| Total debt | — | $20.58M | $20.20M | $4.64M | $0 |
| Total liabilities | $177.25M | $70.76M | $48.40M | $40.03M | $15.99M |
| Shareholders' equity | $722.17M | $671.64M | $442.02M | $395.06M | $187.72M |
| Net debt | — | -$79.01M | -$82.62M | -$150.93M | -$42.30M |
| Shares outstanding | 101.83M | 80.99M | 53.99M | 41.31M | 23.92M |
| Cash flow statement | |||||
| Operating cash flow | -$276.39M | -$232.32M | -$184.17M | -$93.84M | -$54.58M |
| Capital expenditure | $495,000 | $511,000 | $898,000 | $797,000 | $338,000 |
| Free cash flow | -$276.89M | -$232.83M | -$185.07M | -$94.64M | -$54.92M |
| Investing cash flow | -$37.56M | -$228.65M | -$94.25M | -$115.13M | -$74.29M |
| Financing cash flow | $426.74M | $457.74M | $225.67M | $322.24M | $125.28M |
| Depreciation & amortization | $460,000 | $540,000 | $522,000 | $255,000 | $120,000 |
| Stock-based compensation | $44.30M | $42.15M | $67.17M | $19.77M | $14.46M |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.